抗体偶联药物在肺癌中的研究进展★

Research progress of antibody-drug conjugate in lung cancer★

摘要:

肺癌是世界上最常见的恶性肿瘤之一，传统化疗可有限地延长患者生存期，但结果仍不够理想。随着基因检测技术的提升，靶向和免疫治疗显著延长了肺癌患者的生存期，但仍有一部分患者无法从中获益。抗体偶联药物（ADC）是一类具有独特作用机制的抗肿瘤新药，包含具有高度特异性和亲和力的抗体、高效细胞毒药物和高稳定性连接子，兼有传统化疗药物的强大杀伤作用和抗体药物的精确靶向性。目前，不少针对肺癌ADC的基础及临床研究正在开展。本文就ADC在肺癌中的研究进展进行综述。

Abstract:

Lung cancer is one of the most common cancers in the world. Conventional chemotherapy can prolong the survival of lung cancer patients, but the results are still not ideal. With the improvement of gene detection technology, targeted therapy and immunotherapy have significantly prolonged the survival of patients with lung cancer, but a proportion of patients did not benefit from it. Antibody-drug conjugate (ADC) is a kind of antitumor drug with a unique mechanism of action, containing highly specific and affinity antibodies, sufficiently cytotoxic payloads and highly stable linkers, which couple the powerful cancer-killing impact of traditional chemotherapy drugs with the precision of the antibody. Recently, many ADCs targeting lung cancer are undergoing basic research and clinical trials. In this article, we mainly reviewed the recent development of ADCs in the treatment of lung cancer.